Advertisement

Journal of Endocrinological Investigation

, Volume 38, Issue 6, pp 643–651 | Cite as

Inadequacy of initiating rosuvastatin then metformin on biochemical profile of polycystic ovarian syndrome patients

  • G. Ghazeeri
  • H. A. Abbas
  • B. Skaff
  • S. Harajly
  • J. Awwad
Original Article

Abstract

Background

Polycystic ovary syndrome (PCOS) afflicts at least 5 % of women. Both metformin and statin have been used as methods to ameliorate symptoms and improve prognosis.

Aim

To test the efficacy of concomitant usage of metformin and statins in PCOS patients.

Materials and methods

This is a prospective, randomized, double-blinded, placebo controlled study. 37 patients received rosuvastatin (10 mg/day) for a period of 3 months, then the patients were randomly allocated to one of two groups: the first group (or intervention group) received rosuvastatin (10 mg/day) plus metformin (850 mg twice daily after meals), and the second group (referred to as control group hereafter) received rosuvastatin (10 mg/day) plus placebo for a period of 3 months. Biochemical and clinical data were collected at each time point.

Results

There were no significant differences between the intervention and control groups for baseline lipid profile (LDL, HDL, triglycerides, total cholesterol), CRP, homocysteine, DHEAS, testosterone and insulin (p > 0.05 for all variables). There were no significant differences in lipid profile, CRP, homocysteine, DHEAS, testosterone and insulin between the intervention and placebo groups at 3 and 6 months after treatment (p > 0.05 for all). Significant differences in the outcome variables of LDL, total cholesterol and FBS emerged within the intervention group, with significantly higher levels at 6 months compared to 3 months. We also did not find any significant group differences in unit change of the outcome variables between baseline and 3 months.

Conclusions

We found that the combination of statin and metformin has no advantage in PCOS management. In fact, the increase of LDL, total cholesterol and FBS within the intervention group warrants reassessment of current regimens to avoid any patient harm.

Keywords

Rosuvastatin Metformin Polycystic ovarian syndrome Biochemical profile 

Notes

Conflict of interest

Authors declare no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Informed consent

Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.

References

  1. 1.
    Kaya C, Cengiz SD, Berker B, Demirtas S, Cesur M, Erdogan G (2009) Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 92(2):635–642CrossRefPubMedGoogle Scholar
  2. 2.
    Nestler JE (2008) Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 358(1):47–54CrossRefPubMedGoogle Scholar
  3. 3.
    Benson S, Hahn S, Tan S, Janssen OE, Schedlowski M, Elsenbruch S (2010) Maladaptive coping with illness in women with polycystic ovary syndrome. J Obstet Gynecol Neonatal Nurs 39(1):37–45CrossRefPubMedGoogle Scholar
  4. 4.
    Homburg R (2008) Polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 22(2):261–274CrossRefPubMedGoogle Scholar
  5. 5.
    Banaszewska B, Duleba AJ, Spaczynski RZ, Pawelczyk L (2006) Lipids in polycystic ovary syndrome: role of hyperinsulinemia and effects of metformin. Am J Obstet Gynecol 194(5):1266–1272CrossRefPubMedGoogle Scholar
  6. 6.
    Lord JM, Flight IH, Norman RJ (2003) Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327(7421):951–953CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Lord JM, Flight IH, Norman RJ (2003) Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, d-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev (3):CD003053Google Scholar
  8. 8.
    Kazerooni T, Shojaei-Baghini A, Dehbashi S, Asadi N, Ghaffarpasand F, Kazerooni Y (2010) Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study. Fertil Steril 94(6):2208–2213CrossRefPubMedGoogle Scholar
  9. 9.
    de Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM (2011) PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Human Reprod Update 17(4):495–500CrossRefGoogle Scholar
  10. 10.
    Sathyapalan T, Atkin SL (2012) Recent advances in cardiovascular aspects of polycystic ovary syndrome. Eur J Endocrinol 166(4):575–583CrossRefPubMedGoogle Scholar
  11. 11.
    Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Duleba AJ (2007) Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab 92(2):456–461CrossRefPubMedGoogle Scholar
  12. 12.
    Kodaman PH, Duleba AJ (2008) HMG-CoA reductase inhibitors: do they have potential in the treatment of polycystic ovary syndrome? Drugs 68(13):1771–1785CrossRefPubMedGoogle Scholar
  13. 13.
    Kodaman PH, Duleba AJ (2008) Statins in the treatment of polycystic ovary syndrome. Semin Reprod Med 26(1):127–138CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ (2009) Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. J Clin Endocrinol Metab 94(12):4938–4945CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Navali N, Pourabolghasem S, Fouladi RF, Nikpour MA (2011) Therapeutic effects of biguanide vs. statin in polycystic ovary syndrome: a randomized clinical trial. Pak J Biol Sci 14(11):658–663CrossRefPubMedGoogle Scholar
  16. 16.
    Sathyapalan T, Smith KA, Coady AM, Kilpatrick ES, Atkin SL (2012) Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Ann Clin Biochem 49(pt 1):80–85CrossRefPubMedGoogle Scholar
  17. 17.
    Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375(9716):735–742CrossRefPubMedGoogle Scholar
  18. 18.
    Carmina E, Azziz R (2006) Diagnosis, phenotype, and prevalence of polycystic ovary syndrome. Fertil Steril 86(suppl 1):S7–S8CrossRefPubMedGoogle Scholar
  19. 19.
    Agarwal N, Rice SP, Bolusani H, Luzio SD, Dunseath G, Ludgate M et al (2010) Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab 95(2):722–730CrossRefPubMedGoogle Scholar
  20. 20.
    Izquierdo D, Foyouzi N, Kwintkiewicz J, Duleba AJ (2004) Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis. Fertil Steril 82(suppl 3):1193–1197CrossRefPubMedGoogle Scholar
  21. 21.
    Duleba AJ, Banaszewska B, Spaczynski RZ, Pawelczyk L (2006) Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertil Steril 85(4):996–1001CrossRefPubMedGoogle Scholar
  22. 22.
    Sathyapalan T, Shepherd J, Coady AM, Kilpatrick ES, Atkin SL (2012) Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 97(11):3951–3955CrossRefPubMedGoogle Scholar
  23. 23.
    Raval AD, Hunter T, Stuckey B, Hart RJ (2011) Statins for women with polycystic ovary syndrome not actively trying to conceive. Cochrane Database Syst Rev (10):CD008565Google Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2015

Authors and Affiliations

  • G. Ghazeeri
    • 1
  • H. A. Abbas
    • 1
    • 2
  • B. Skaff
    • 1
  • S. Harajly
    • 1
  • J. Awwad
    • 1
  1. 1.Department of Obstetrics and GynecologyAmerican University of Beirut Medical CenterBeirutLebanon
  2. 2.Faculty of MedicineAmerican University of BeirutBeirutLebanon

Personalised recommendations